New Delhi, March 23 -- Sai Parenterals, a diversified pharmaceutical formulations company with capabilities in research, development, and manufacturing, and engaged in the business of branded generic formulations and contract development and manufacturing organisation (CDMO) products, has garnered Rs.122.6 crore from anchor investors ahead of its initial public offering, which opens for public subscription on Tuesday, March 24, 2026.

The company informed the bourses that it allocated 31,28,458 equity shares at Rs.392 per share to anchor investors. Some of the marquee institutions that participated in the anchor book include Morgan Stanley (Asia) Singapore Pte, Kotak Mahindra Life Insurance Company, Kotak Life Sciences Fund 1, and India E...